

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version 1.3      Revision Date: 09.04.2021      SDS Number: 4983460-00004      Date of last issue: 10.10.2020  
Date of first issue: 30.09.2019

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1 Product identifier

Trade name : Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Substance/Mixture : Pharmaceutical

#### 1.3 Details of the supplier of the safety data sheet

Company : Organon & Co.  
Shotton Lane  
NE23 3JU Cramlington NU - Great Britain

Telephone : 44 1 670 59 30 00

E-mail address of person responsible for the SDS : EHSSTEWARD@organon.com

#### 1.4 Emergency telephone number

215-631-6999

### SECTION 2: Hazards identification

#### 2.1 Classification of the substance or mixture

##### Classification (REGULATION (EC) No 1272/2008)

Eye irritation, Category 2	H319: Causes serious eye irritation.
Reproductive toxicity, Category 1A	H360D: May damage the unborn child.
Specific target organ toxicity - repeated exposure, Category 2	H373: May cause damage to organs through prolonged or repeated exposure.
Long-term (chronic) aquatic hazard, Category 3	H412: Harmful to aquatic life with long lasting effects.

#### 2.2 Label elements

##### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :

Signal word : Danger

Hazard statements : H319 Causes serious eye irritation.  
H360D May damage the unborn child.  
H373 May cause damage to organs through prolonged or repeated exposure.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version 1.3      Revision Date: 09.04.2021      SDS Number: 4983460-00004      Date of last issue: 10.10.2020  
Date of first issue: 30.09.2019

H412 Harmful to aquatic life with long lasting effects.

Precautionary statements : **Prevention:**

P201 Obtain special instructions before use.

P260 Do not breathe dust.

P273 Avoid release to the environment.

P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

P337 + P313 If eye irritation persists: Get medical advice/ attention.

**Hazardous components which must be listed on the label:**

Olmesartan

Hydrochlorothiazide

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

May form explosible dust-air mixture if dispersed.

Contact with dust can cause mechanical irritation or drying of the skin.

## SECTION 3: Composition/information on ingredients

### 3.2 Mixtures

#### Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Olmesartan	144689-63-4	Acute Tox. 4; H302 Eye Irrit. 2; H319 Repr. 1A; H360D	>= 10 - < 20
Hydrochlorothiazide	58-93-5 200-403-3	STOT RE 1; H372 (Kidney, Parathyroid gland)	>= 1 - < 10
Amlodipine Besylate	652969-01-2	Acute Tox. 4; H302 Eye Irrit. 2; H319 Aquatic Chronic 2; H411	>= 2.5 - < 10

For explanation of abbreviations see section 16.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.3	09.04.2021	4983460-00004	Date of first issue: 30.09.2019

---

### SECTION 4: First aid measures

#### 4.1 Description of first aid measures

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.  
If easy to do, remove contact lens, if worn.  
Get medical attention.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.

#### 4.2 Most important symptoms and effects, both acute and delayed

- Risks : Causes serious eye irritation.  
May damage the unborn child.  
May cause damage to organs through prolonged or repeated exposure.
- Contact with dust can cause mechanical irritation or drying of the skin.

#### 4.3 Indication of any immediate medical attention and special treatment needed

- Treatment : Treat symptomatically and supportively.
- 

### SECTION 5: Firefighting measures

#### 5.1 Extinguishing media

- Suitable extinguishing media : Water spray  
Alcohol-resistant foam
-

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.3	09.04.2021	4983460-00004	Date of first issue: 30.09.2019

Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : High volume water jet

### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.  
Do not use a solid water stream as it may scatter and spread fire.  
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides  
Nitrogen oxides (NO<sub>x</sub>)  
Chlorine compounds  
Sulphur oxides

### 5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

## SECTION 6: Accidental release measures

### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.3	09.04.2021	4983460-00004	Date of first issue: 30.09.2019

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

## SECTION 7: Handling and storage

### 7.1 Precautions for safe handling

- |                         |   |   |
|-------------------------|---|---|
| Technical measures      | : | Static electricity may accumulate and ignite suspended dust causing an explosion.<br>Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.  |
| Local/Total ventilation | : | If sufficient ventilation is unavailable, use with local exhaust ventilation.   |
| Advice on safe handling | : | Do not get on skin or clothing.<br>Do not breathe dust.<br>Do not swallow.<br>Do not get in eyes.<br>Wash skin thoroughly after handling.<br>Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment<br>Keep container tightly closed.<br>Minimize dust generation and accumulation.<br>Keep container closed when not in use.<br>Keep away from heat and sources of ignition.<br>Do not eat, drink or smoke when using this product.<br>Take care to prevent spills, waste and minimize release to the environment. |
| Hygiene measures        | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.<br>The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.  |

### 7.2 Conditions for safe storage, including any incompatibilities

- |   |   |   |
|---|---|---|
| Requirements for storage areas and containers | : | Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations. |
|---|---|---|

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version 1.3      Revision Date: 09.04.2021      SDS Number: 4983460-00004      Date of last issue: 10.10.2020  
Date of first issue: 30.09.2019

Advice on common storage : Do not store with the following product types:  
Strong oxidizing agents  
Organic peroxides  
Explosives  
Gases

### 7.3 Specific end use(s)

Specific use(s) : No data available

## SECTION 8: Exposure controls/personal protection

### 8.1 Control parameters

#### Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Cellulose	9004-34-6	TWA (inhalable dust)	10 mg/m <sup>3</sup>	GB EH40
		Further information: For the purposes of these limits, respirable dust and inhalable dust are those fractions of airborne dust which will be collected when sampling is undertaken in accordance with the methods described in MDHS14/4 General methods for sampling and gravimetric analysis or respirable, thoracic and inhalable aerosols., The COSHH definition of a substance hazardous to health includes dust of any kind when present at a concentration in air equal to or greater than 10 mg.m <sup>-3</sup> 8-hour TWA of inhalable dust or 4 mg.m <sup>-3</sup> 8-hour TWA of respirable dust. This means that any dust will be subject to COSHH if people are exposed to dust above these levels. Some dusts have been assigned specific WELs and exposure to these must comply with the appropriate limits., Most industrial dusts contain particles of a wide range of sizes. The behaviour, deposition and fate of any particular particle after entry into the human respiratory system, and the body response that it elicits, depend on the nature and size of the particle. HSE distinguishes two size fractions for limit-setting purposes termed 'inhalable' and 'respirable'. Inhalable dust approximates to the fraction of airborne material that enters the nose and mouth during breathing and is therefore available for deposition in the respiratory tract. Respirable dust approximates to the fraction that penetrates to the gas exchange region of the lung. Fuller definitions and explanatory material are given in MDHS14/4., Where dusts contain components that have their own assigned WEL, all the relevant limits should be complied with.		
		TWA (Respirable dust)	4 mg/m <sup>3</sup>	GB EH40
		Further information: For the purposes of these limits, respirable dust and inhalable dust are those fractions of airborne dust which will be collected when sampling is undertaken in accordance with the methods described in MDHS14/4 General methods for sampling and gravimetric analysis or respirable, thoracic and inhalable aerosols., The COSHH definition of a substance hazardous to health includes dust of any kind when present at a concentration in air equal to or greater than 10 mg.m <sup>-3</sup> 8-hour TWA of inhalable dust or 4 mg.m <sup>-3</sup> 8-hour TWA of respirable dust. This means that any dust will be sub-		

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version 1.3      Revision Date: 09.04.2021      SDS Number: 4983460-00004      Date of last issue: 10.10.2020  
 Date of first issue: 30.09.2019

	<p>ject to COSHH if people are exposed to dust above these levels. Some dusts have been assigned specific WELs and exposure to these must comply with the appropriate limits., Most industrial dusts contain particles of a wide range of sizes. The behaviour, deposition and fate of any particular particle after entry into the human respiratory system, and the body response that it elicits, depend on the nature and size of the particle. HSE distinguishes two size fractions for limit-setting purposes termed 'inhalable' and 'respirable'. Inhalable dust approximates to the fraction of airborne material that enters the nose and mouth during breathing and is therefore available for deposition in the respiratory tract. Respirable dust approximates to the fraction that penetrates to the gas exchange region of the lung. Fuller definitions and explanatory material are given in MDHS14/4., Where dusts contain components that have their own assigned WEL, all the relevant limits should be complied with.</p>			
		STEL (inhalable dust)	20 mg/m <sup>3</sup>	GB EH40
	<p>Further information: For the purposes of these limits, respirable dust and inhalable dust are those fractions of airborne dust which will be collected when sampling is undertaken in accordance with the methods described in MDHS14/4 General methods for sampling and gravimetric analysis or respirable, thoracic and inhalable aerosols., The COSHH definition of a substance hazardous to health includes dust of any kind when present at a concentration in air equal to or greater than 10 mg.m<sup>-3</sup> 8-hour TWA of inhalable dust or 4 mg.m<sup>-3</sup> 8-hour TWA of respirable dust. This means that any dust will be subject to COSHH if people are exposed to dust above these levels. Some dusts have been assigned specific WELs and exposure to these must comply with the appropriate limits., Most industrial dusts contain particles of a wide range of sizes. The behaviour, deposition and fate of any particular particle after entry into the human respiratory system, and the body response that it elicits, depend on the nature and size of the particle. HSE distinguishes two size fractions for limit-setting purposes termed 'inhalable' and 'respirable'. Inhalable dust approximates to the fraction of airborne material that enters the nose and mouth during breathing and is therefore available for deposition in the respiratory tract. Respirable dust approximates to the fraction that penetrates to the gas exchange region of the lung. Fuller definitions and explanatory material are given in MDHS14/4., Where dusts contain components that have their own assigned WEL, all the relevant limits should be complied with.</p>			
Starch	9005-25-8	TWA (inhalable dust)	10 mg/m <sup>3</sup>	GB EH40
	<p>Further information: For the purposes of these limits, respirable dust and inhalable dust are those fractions of airborne dust which will be collected when sampling is undertaken in accordance with the methods described in MDHS14/4 General methods for sampling and gravimetric analysis or respirable, thoracic and inhalable aerosols., The COSHH definition of a substance hazardous to health includes dust of any kind when present at a concentration in air equal to or greater than 10 mg.m<sup>-3</sup> 8-hour TWA of inhalable dust or 4 mg.m<sup>-3</sup> 8-hour TWA of respirable dust. This means that any dust will be subject to COSHH if people are exposed to dust above these levels. Some dusts have been assigned specific WELs and exposure to these must comply with the appropriate limits., Most industrial dusts contain particles of a wide range of sizes. The behaviour, deposition and fate of any particular particle after entry into the human respiratory system, and the body response that it elicits, depend on the nature and size of the particle. HSE distinguishes two size</p>			

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version 1.3      Revision Date: 09.04.2021      SDS Number: 4983460-00004      Date of last issue: 10.10.2020  
Date of first issue: 30.09.2019

	fractions for limit-setting purposes termed 'inhalable' and 'respirable'. Inhalable dust approximates to the fraction of airborne material that enters the nose and mouth during breathing and is therefore available for deposition in the respiratory tract. Respirable dust approximates to the fraction that penetrates to the gas exchange region of the lung. Fuller definitions and explanatory material are given in MDHS14/4. Where dusts contain components that have their own assigned WEL, all the relevant limits should be complied with. Where no specific short-term exposure limit is listed, a figure three times the long-term exposure limit should be used.			
		TWA (Respirable dust)	4 mg/m <sup>3</sup>	GB EH40
	Further information: For the purposes of these limits, respirable dust and inhalable dust are those fractions of airborne dust which will be collected when sampling is undertaken in accordance with the methods described in MDHS14/4 General methods for sampling and gravimetric analysis or respirable, thoracic and inhalable aerosols. The COSHH definition of a substance hazardous to health includes dust of any kind when present at a concentration in air equal to or greater than 10 mg.m <sup>-3</sup> 8-hour TWA of inhalable dust or 4 mg.m <sup>-3</sup> 8-hour TWA of respirable dust. This means that any dust will be subject to COSHH if people are exposed to dust above these levels. Some dusts have been assigned specific WELs and exposure to these must comply with the appropriate limits. Most industrial dusts contain particles of a wide range of sizes. The behaviour, deposition and fate of any particular particle after entry into the human respiratory system, and the body response that it elicits, depend on the nature and size of the particle. HSE distinguishes two size fractions for limit-setting purposes termed 'inhalable' and 'respirable'. Inhalable dust approximates to the fraction of airborne material that enters the nose and mouth during breathing and is therefore available for deposition in the respiratory tract. Respirable dust approximates to the fraction that penetrates to the gas exchange region of the lung. Fuller definitions and explanatory material are given in MDHS14/4. Where dusts contain components that have their own assigned WEL, all the relevant limits should be complied with. Where no specific short-term exposure limit is listed, a figure three times the long-term exposure limit should be used.			
Olmesartan	144689-63-4	TWA	30 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	300 µg/100 cm <sup>2</sup>	Internal
Hydrochlorothiazide	58-93-5	TWA	100 µg/m <sup>3</sup> (OEB 2)	Internal
Amlodipine Besylate	652969-01-2	TWA	20 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	100 µg/100 cm <sup>2</sup>	Internal

### 8.2 Exposure controls

#### Engineering measures

Use feasible engineering controls to minimize exposure to compound.  
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

#### Personal protective equipment

Eye protection : Wear safety glasses with side shields or goggles.



# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.3	09.04.2021	4983460-00004	Date of first issue: 30.09.2019

If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection		
Material	:	Chemical-resistant gloves
Skin and body protection	:	Work uniform or laboratory coat.
Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Equipment should conform to BS EN 143
Filter type	:	Particulates type (P)

### SECTION 9: Physical and chemical properties

#### 9.1 Information on basic physical and chemical properties

Appearance	:	tablet
Colour	:	No data available
Odour	:	No data available
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	No data available
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	Not applicable
Relative vapour density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies)	:	

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.3	09.04.2021	4983460-00004	Date of first issue: 30.09.2019

Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity	:	
Viscosity, kinematic	:	Not applicable
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.

### 9.2 Other information

Molecular weight	:	No data available
Particle size	:	No data available

---

## SECTION 10: Stability and reactivity

### 10.1 Reactivity

Not classified as a reactivity hazard.

### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

Hazardous reactions	:	Dust can form an explosive mixture in air. Can react with strong oxidizing agents.
---------------------	---	---

### 10.4 Conditions to avoid

Conditions to avoid	:	Avoid dust formation.
---------------------	---	-----------------------

### 10.5 Incompatible materials

Materials to avoid	:	Oxidizing agents
--------------------	---	------------------

### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

---

## SECTION 11: Toxicological information

### 11.1 Information on toxicological effects

Information on likely routes of exposure	:	Inhalation Skin contact Ingestion Eye contact
--	---	--

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version 1.3      Revision Date: 09.04.2021      SDS Number: 4983460-00004      Date of last issue: 10.10.2020  
Date of first issue: 30.09.2019

---

### Acute toxicity

Not classified based on available information.

### Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg  
Method: Calculation method

### Components:

#### Olmesartan:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg  
LD50 (Mouse): > 2,000 mg/kg  
LD50 (Dog): > 1,500 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

#### Hydrochlorothiazide:

Acute oral toxicity : LD50 (Rat): > 2,750 mg/kg  
LD50 (Mouse): > 2,830 mg/kg

Acute toxicity (other routes of administration) : LD50 (Rat): 990 mg/kg  
Application Route: Intravenous  
LD50 (Mouse): 590 mg/kg  
Application Route: Intravenous

#### Amlodipine Besylate:

Acute oral toxicity : LD50 (Rat): 393 mg/kg

### Skin corrosion/irritation

Not classified based on available information.

### Components:

#### Olmesartan:

Remarks : No data available

#### Hydrochlorothiazide:

Species : Rabbit  
Result : No skin irritation

### Serious eye damage/eye irritation

Causes serious eye irritation.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version 1.3      Revision Date: 09.04.2021      SDS Number: 4983460-00004      Date of last issue: 10.10.2020  
Date of first issue: 30.09.2019

---

### Components:

#### **Olmesartan:**

Species : Rabbit  
Method : Draize Test  
Result : Moderate eye irritation

#### **Hydrochlorothiazide:**

Species : Rabbit  
Result : Mild eye irritation

#### **Amlodipine Besylate:**

Species : Rabbit  
Result : Severe irritation

### **Respiratory or skin sensitisation**

#### **Skin sensitisation**

Not classified based on available information.

#### **Respiratory sensitisation**

Not classified based on available information.

### Components:

#### **Olmesartan:**

Exposure routes : Skin contact  
Remarks : No data available

### **Germ cell mutagenicity**

Not classified based on available information.

### Components:

#### **Olmesartan:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Mutagenicity (in vitro mammalian cytogenetic test)  
Result: negative

Test Type: Chromosome aberration test in vitro  
Test system: Chinese hamster lung cells  
Result: positive

Test Type: Mouse Lymphoma  
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Mouse  
Cell type: Bone marrow

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.3	09.04.2021	4983460-00004	Date of first issue: 30.09.2019

Application Route: Oral  
Result: negative

Germ cell mutagenicity- Assessment : Weight of evidence does not support classification as a germ cell mutagen.

### Hydrochlorothiazide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Chromosomal aberration  
Test system: Chinese hamster ovary cells  
Result: negative

Test Type: sister chromatid exchange assay  
Test system: Chinese hamster ovary cells  
Result: positive

Test Type: in vitro assay  
Test system: mouse lymphoma cells  
Result: positive

Genotoxicity in vivo : Test Type: Chromosomal aberration  
Species: Chinese hamster  
Cell type: Bone marrow  
Result: negative

Test Type: in vivo assay  
Species: Mouse  
Cell type: Bone marrow  
Result: negative

Germ cell mutagenicity- Assessment : Weight of evidence does not support classification as a germ cell mutagen.

### Amlodipine Besylate:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Chromosome aberration test in vitro  
Result: negative

### Carcinogenicity

Not classified based on available information.

### Components:

#### Olmesartan:

Species : Rat  
Application Route : Oral  
Exposure time : 2 Years

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version 1.3      Revision Date: 09.04.2021      SDS Number: 4983460-00004      Date of last issue: 10.10.2020  
Date of first issue: 30.09.2019

Result : negative

Species : Mouse  
Application Route : Oral  
Exposure time : 6 Months  
Result : negative

### Hydrochlorothiazide:

Species : Mouse, female  
Application Route : Oral  
Exposure time : 2 Years  
Result : negative

Species : Mouse, male  
Application Route : Oral  
Exposure time : 2 Years  
Result : equivocal

Species : Rat, male and female  
Application Route : Oral  
Exposure time : 2 Years  
Result : negative

### Amlodipine Besylate:

Species : Mouse  
Application Route : Oral  
Exposure time : 2 Years  
Result : negative

Species : Rat  
Application Route : Oral  
Exposure time : 2 Years  
Result : negative

### Reproductive toxicity

May damage the unborn child.

### Components:

#### Olmesartan:

Effects on fertility : Test Type: Fertility  
Species: Rat  
Application Route: Oral  
Fertility: NOAEL: 1,000 mg/kg body weight  
Result: No effects on fertility

Effects on foetal development : Test Type: Development  
Species: Rat  
Application Route: Oral  
Dose: 1000 milligram per kilogram  
Result: No teratogenic effects

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.3	09.04.2021	4983460-00004	Date of first issue: 30.09.2019

Test Type: Development  
Species: Rabbit  
Application Route: Oral  
Dose: 1 milligram per kilogram  
Result: No teratogenic effects

Test Type: Development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: LOAEL:  $\geq$  1.6 mg/kg body weight  
Symptoms: Malformations were observed., Reduced body weight  
Result: Effects on postnatal development

Reproductive toxicity - Assessment : Positive evidence of adverse effects on development from human epidemiological studies.

### Hydrochlorothiazide:

Effects on fertility

: Test Type: Fertility  
Species: Rat, male and female  
Application Route: oral (feed)  
Fertility: NOAEL: 4 mg/kg body weight  
Result: Effects on fertility

Test Type: Fertility  
Species: Mouse, male and female  
Application Route: oral (feed)  
Fertility: NOAEL: 100 mg/kg body weight  
Result: Effects on fertility

Effects on foetal development

: Test Type: Development  
Species: Mouse  
Application Route: Oral  
Developmental Toxicity: NOAEL: 3,000 mg/kg body weight  
Result: No teratogenic effects

Test Type: Development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: NOAEL: 1,000 mg/kg body weight  
Result: No teratogenic effects

### Amlodipine Besylate:

Effects on fertility

: Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
Fertility: NOAEL: 10 mg/kg body weight  
Result: No effects on fertility

Test Type: Fertility/early embryonic development

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.3	09.04.2021	4983460-00004	Date of first issue: 30.09.2019

Species: Rabbit  
Application Route: Ingestion  
Fertility: NOAEL: 25 mg/kg body weight  
Result: No effects on fertility

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Ingestion  
Developmental Toxicity: LOAEL: 10 mg/kg body weight  
Result: Effects on foetal development

Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Ingestion  
Developmental Toxicity: NOAEL: 10 mg/kg body weight  
Result: No effects on foetal development

Test Type: Embryo-foetal development  
Species: Mouse  
Application Route: Ingestion  
Developmental Toxicity: LOAEL: 1.6 mg/kg body weight  
Result: Effects on foetal development  
Remarks: Maternal toxicity observed.

### STOT - single exposure

Not classified based on available information.

### STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

### Components:

#### Hydrochlorothiazide:

Target Organs : Kidney, Parathyroid gland  
Assessment : Causes damage to organs through prolonged or repeated exposure.

### Repeated dose toxicity

### Components:

#### Olmesartan:

Species : Rat  
NOAEL : 2,000 mg/kg  
Application Route : Oral  
Exposure time : 24 Months  
Remarks : No significant adverse effects were reported

#### Hydrochlorothiazide:

Species : Rat, male and female  
LOAEL : 10 mg/kg  
Application Route : Oral



# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version 1.3      Revision Date: 09.04.2021      SDS Number: 4983460-00004      Date of last issue: 10.10.2020  
Date of first issue: 30.09.2019

Exposure time : 2 yr  
Target Organs : Kidney, Parathyroid gland

Species : Mouse, male and female  
NOAEL : 300 - 550 mg/kg  
Application Route : Oral  
Exposure time : 2 yr  
Remarks : No significant adverse effects were reported

Species : Dog  
: 50 - 200 mg/kg  
Application Route : Oral  
Exposure time : 9 Months  
Target Organs : Parathyroid gland

### Amlodipine Besylate:

Species : Rat  
NOAEL : 15 mg/kg  
Application Route : Oral  
Exposure time : 90 d  
Remarks : No significant adverse effects were reported

### Aspiration toxicity

Not classified based on available information.

### Components:

#### Hydrochlorothiazide:

No aspiration toxicity classification

### Experience with human exposure

### Components:

#### Olmesartan:

Eye contact : Symptoms: Eye irritation  
Ingestion : Symptoms: hypotension  
Remarks: May cause harm to the unborn child.  
Based on Human Evidence

#### Hydrochlorothiazide:

Eye contact : Symptoms: Eye irritation  
Ingestion : Symptoms: Dizziness, Headache, Fatigue, Nausea, Abdominal pain, hypotension, dry mouth, electrolyte imbalance, eye pain

#### Amlodipine Besylate:

Eye contact : Symptoms: Severe irritation  
Ingestion : Symptoms: Nausea, Abdominal pain, Fatigue, Headache, Oedema, Palpitation

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.3	09.04.2021	4983460-00004	Date of first issue: 30.09.2019

### SECTION 12: Ecological information

#### 12.1 Toxicity

##### Components:

##### **Hydrochlorothiazide:**

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 500 mg/l  
Exposure time: 96 h

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): > 500 mg/l  
aquatic invertebrates Exposure time: 48 h

##### **Amlodipine Besylate:**

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 2.7 mg/l  
Exposure time: 96 h

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): 3.2 mg/l  
aquatic invertebrates Exposure time: 48 h

Toxicity to algae/aquatic : IC50 (Pseudokirchneriella subcapitata (green algae)): 5.6 mg/l  
plants Exposure time: 72 h  
Method: OECD Test Guideline 201

#### 12.2 Persistence and degradability

##### Components:

##### **Hydrochlorothiazide:**

Stability in water : Hydrolysis: 46.2 %(96 h)

#### 12.3 Bioaccumulative potential

##### Components:

##### **Amlodipine Besylate:**

Partition coefficient: n- : log Pow: 3  
octanol/water

#### 12.4 Mobility in soil

No data available

#### 12.5 Results of PBT and vPvB assessment

##### Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.3	09.04.2021	4983460-00004	Date of first issue: 30.09.2019

### 12.6 Other adverse effects

#### **Product:**

Endocrine disrupting potential : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

## SECTION 13: Disposal considerations

### 13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

## SECTION 14: Transport information

### 14.1 UN number

Not regulated as a dangerous good

### 14.2 UN proper shipping name

Not regulated as a dangerous good

### 14.3 Transport hazard class(es)

Not regulated as a dangerous good

### 14.4 Packing group

Not regulated as a dangerous good

### 14.5 Environmental hazards

Not regulated as a dangerous good

### 14.6 Special precautions for user

Not applicable

### 14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

## SECTION 15: Regulatory information

### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII) : Not applicable

REACH - Candidate List of Substances of Very High : Not applicable

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.3	09.04.2021	4983460-00004	Date of first issue: 30.09.2019

Concern for Authorisation (Article 59).

REACH - List of substances subject to authorisation (Annex XIV) : Not applicable

Regulation (EC) No 1005/2009 on substances that deplete the ozone layer : Not applicable

Regulation (EU) 2019/1021 on persistent organic pollutants (recast) : Not applicable

Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals : Not applicable

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.  
Not applicable

### Other regulations:

Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.

Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

### The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

## 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

## SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

### Full text of H-Statements

H302 : Harmful if swallowed.

H319 : Causes serious eye irritation.

H360D : May damage the unborn child.

H372 : Causes damage to organs through prolonged or repeated exposure.

H411 : Toxic to aquatic life with long lasting effects.

### Full text of other abbreviations

Acute Tox. : Acute toxicity

Aquatic Chronic : Long-term (chronic) aquatic hazard

Eye Irrit. : Eye irritation

Repr. : Reproductive toxicity

STOT RE : Specific target organ toxicity - repeated exposure

GB EH40 : UK. EH40 WEL - Workplace Exposure Limits

GB EH40 / TWA : Long-term exposure limit (8-hour TWA reference period)

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.3	09.04.2021	4983460-00004	Date of first issue: 30.09.2019

GB EH40 / STEL : Short-term exposure limit (15-minute reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

### Classification of the mixture:

Eye Irrit. 2	H319
Repr. 1A	H360D
STOT RE 2	H373
Aquatic Chronic 3	H412

### Classification procedure:

Calculation method
Calculation method
Calculation method
Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS mate-

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.3	09.04.2021	4983460-00004	Date of first issue: 30.09.2019

---

Material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

GB / EN